Quick Dispatch:
Your surmount 1 tirzepatide SURMOUNT-1 (NEJM 2022) tested tirzepatide — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean weight loss at the highest dose. 57% of participants orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your surmount 1 tirzepatide SURMOUNT-1 (NEJM 2022) tested tirzepatide — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean weight loss at the highest dose. 57% of participants ships.
Need Help?
Questions about surmount 1 tirzepatide SURMOUNT-1 (NEJM 2022) tested tirzepatide — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean weight loss at the highest dose. 57% of participants, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for surmount 1 tirzepatide SURMOUNT-1 (NEJM 2022) tested tirzepatide — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean weight loss at the highest dose. 57% of participants in your area.
SURMOUNT-1: Adults achieve weight loss of 16% or more at 72 weeks with tirzepatide
21.04
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
21.22
Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program - Roux - 2023 - Obesity
24.90
SURMOUNT 1 // Three-Year Obesty & Diabetes Prevention Outcomes
27.16
Tirzepatide's Surmount-4 Trial Reveals Groundbreaking Results
20.04
Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial
20.02
Time to weight plateau with tirzepatide treatment in the SURMOUNT‐1 and SURMOUNT‐4 clinical trials - Horn - 2025 - Clinical Obesity
29.92
